Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
出版年份 2020 全文链接
标题
Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
作者
关键词
-
出版物
Clinical Pharmacology in Drug Development
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-08-21
DOI
10.1002/cpdd.855
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
- (2020) Daisuke Sueta et al. CURRENT HYPERTENSION REPORTS
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Adverse effects of mineralocorticoid receptor antagonist administration
- (2019) Manolis S. Kallistratos et al. CURRENT PHARMACEUTICAL DESIGN
- New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
- (2019) Irene Capelli et al. JOURNAL OF NEPHROLOGY
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes
- (2018) Megumi Oshima et al. PLoS One
- The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18
- (2018) Xue-Lian Zhang et al. Therapeutics and Clinical Risk Management
- A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
- (2017) Shigehiro Katayama et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Aldosterone Blockade in CKD: Emphasis on Pharmacology
- (2015) Michael H. Schwenk et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Evidence-based Clinical Practice Guideline for CKD 2013
- (2014) Clinical and Experimental Nephrology
- Aldosterone Blockade in Chronic Kidney Disease
- (2014) Jamie S. Hirsch et al. SEMINARS IN NEPHROLOGY
- Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes
- (2013) Takashi Wada et al. Clinical and Experimental Nephrology
- Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy
- (2013) Thomas A. Mavrakanas et al. European Journal of Internal Medicine
- The Impacts of Albuminuria and Low eGFR on the Risk of Cardiovascular Death, All-Cause Mortality, and Renal Events in Diabetic Patients: Meta-Analysis
- (2013) Tadashi Toyama et al. PLoS One
- Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan
- (2012) Takako Saito et al. HEART AND VESSELS
- Mineralocorticoid receptor antagonists: their use and differentiation in Japan
- (2012) Atsuhisa Sato HYPERTENSION RESEARCH
- Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
- (2012) GianLuca Colussi et al. JOURNAL OF HYPERTENSION
- The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
- (2011) Rena J Eudy et al. Journal of Translational Medicine
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now